Uterine leiomyomas (fibroids) are the most common gynecological neoplasms and may be associated with significant morbidity. Recently, we described a rat model (Eker rat) of fibroid development in which reproductive tract leiomyomas develop spontaneously with high frequency. The present studies describe the estrogen and antiestrogen responsiveness of an Eker rat leiomyoma-derived cell line in vitro and a nude mouse xenograft system in. vivo. In this cell line, estradiol stimulated growth in estrogen-depleted medium, whereas the nonsteroidal antiestrogen tamoxifen maximally inhibited cell proliferation in medium containing 10% charcoal-stripped serum. Proliferation was also decreased by the biologically active tamoxifen metabolite 4-hydroxytamoxifen; the metabolite was more effective than the parent compound in exerting this growth inhibition. Compared to placebo-treated controls, estradiol increased the size of tumors that developed in a nude mouse xenograft system, whereas tamoxifen increased tumor latency and decreased tumor size. This study of leiomyoma cells in a well defined system suggests that antiestrogens may prove efficacious in the treatment of this clinically important neoplasm. (Endocrinology 136: 4996-5003, 1995) 
in vitro and a nude mouse xenograft system in. vivo. In this cell line, estradiol stimulated growth in estrogen-depleted medium, whereas the nonsteroidal antiestrogen tamoxifen maximally inhibited cell proliferation in medium containing 10% charcoal-stripped serum. Proliferation was also decreased by the biologically active tamoxifen metabolite 4-hydroxytamoxifen; the metabolite was more effective than the parent compound in exerting this growth inhibition. Compared to placebo-treated controls, estradiol increased the size of tumors that developed in a nude mouse xenograft system, whereas tamoxifen increased tumor latency and decreased tumor size. This study of leiomyoma cells in a well defined system suggests that antiestrogens may prove efficacious in the treatment of this clinically important neoplasm. (Endocrinology 136: 4996-5003, 1995) U TERINE leiomyomas (fibroids) occur in 20-25% of all women during the decades of reproductive life (1) . Although leiomyomas are considered benign, up to 50% of these tumors may be associated with considerable morbidity (1) . The clinical significance of these tumors is reflected in the facts that adequate medicinal agents are not currently available for myoma therapy, and 200,000 women annually undergo hysterectomy for this condition (2) . Due to the high incidence, detrimental biological effects, and lack of satisfactory nonsurgical treatment regimens for uterine leiomyomas, these tumors have a substantial impact on the health of large numbers of women.
Despite the startling frequency at which leiomyomas occur, little information is available on their etiology, and the responses of these lesions to steroid hormones have not been examined in any systematic fashion. Clinical data, however, suggest that leiomyomas respond to steroid hormones. Fibroids are typically diagnosed during the decades of reproductive life, may increase in size during pregnancy, and often decrease in size after menopause (1) . The effectiveness of GnRH agonists in shrinking these tumors also argues that their growth may be modulated by steroid hormones (3) (4) (5) . Because of the temporal association of tumor growth with the reproductive years and pregnancy, estrogen has received much attention as a possible mediator of leiomyoma development.
The triphenylethylene antiestrogen tamoxifen has been used extensively in the treatment of clinical breast cancer (6) . Although tamoxifen administration has been associated with possible increased risk of endometrial carcinoma (7) , little information is available on the effects of this compound on myometrial growth and proliferation. Responses to tamoxifen are species and tissue specific (81, and the effects of tamoxifen on leiomyomas as a group have yet to be elucidated. This fact becomes especially important because of the high incidence of leiomyoma in the general population. Tamoxifen is currently being evaluated as a preventative for breast cancer (6) , and the effects of this compound on the female population, which has a high background incidence of myometrial tumors, should be considered.
Systematic studies on the roles of hormones and antihormones in leiomyoma development have been hampered because no animal model for the human condition has been previously available. However, we recently described the novel Eker rat model in which reproductive tract leiomybmas arise spontaneously with high frequency (9,lO) . These tumors arise as part of a hereditary cancer syndrome resulting from a germline mutation in what has recently been identified as the tuberous sclerosis 2 gene (11) (12) (13) (14) . In this model system, we evaluated the responses of rat leiomyoma to estrogen, the antiestrogen tamoxifen, and its biologically active (15) metabolite 4-hydroxytamoxifen. Cell proliferation was used to evaluate the in vitro responses of a leiomyomaderived cell line to these compounds. In addition, the ability of estradiol and tamoxifen to modulate the in viva growth of leiomyoma cells in a nude mouse xenograft assay was de-termined, providing extension and validation of in vitro data in an in vivo system.
Materials and Methods

Cell culture
The Eker rat uterine leiomyoma-derived cell line ELT 3 was maintained and propagated in medium as previously described (9) . ELT 3 is of confirmed smooth muscle origin and is estrogen receptor positive, as assessed by Northern blot and specific binding analysis (9) . Cells were grown on plastic (Corning, Corning,NY) in a medium consisting of Ham's F-12Dulbecco's Modified Eagle's Medium (DMEM; GIBCO-BRL, Grand Island, NY) in equal amounts with 1.6 X 1OP M ferrous sulfate (Siama Chemical Co., St. Louis, MO). 1.2 X 10m5 U/ml vasopressin (Siima), 1.0 x 10m9 d T, (Sigma), 0.025 mg/ml insulin (Sigma), 1.0 X 10-s M cholesterol (Sigma), 2.0 X 10e7 M hydrocortisone (Sigma), and 10 pg/ml transferrin (Sigma) supplemented with 10% fetal bovine serum PBS; Hyclone Laboratories, Logan, UT; termed DF8 medium) and 50% 3T3 fibroblast-conditioned medium. The 3T3-conditioned medium was obtained by plating Swiss 3T3 cells at 25% confluence in DMEM supplemented with 10% calf serum (Colorado Serum Co., Denver, CO). After 3-4 days, this medium was harvested and filtered through a 0.45~pm cellulose acetate filter (Coming). The final medium preparation of DF8 and 3T3-conditioned media was termed 50:50. The cultures were maintained in a humidified 5% CO, atmosphere at 37 C and subcultured every 4-7 days with 0.05% trypsin-0.02% EDTA (GIBCO) in PBS (GIBCO). Variations of the 50:50 propagative medium used to evaluate estrogen and antiestrogen responsiveness are indicated in the sections below.
Estrogen responsiveness of ELT 3 cells
The estrogen responsiveness of ELT 3 cells was measured by plating cells in either 50:50 or DF8 medium into 24-well plastic tissue culture dishes (Coming) at lo3 cells/well. Cells were allowed to plate for 24 h. Thev were then rinsed with sterile PBS and refed phenol red-free DF8 (using phenol red-free DMEM and F-12; GIBCO) cbntaining 10% charcoal-stripped FBS, verified by the manufacturer to contain less than 5.0 pg/ml 17a-e&radio1 (Hyclone). After 48 h, this medium was replaced with phenol red-free DFS with 10% charcoal-stripped FBS supplemented with 0.1% ethanol (vehicle control) or 178-estradiol at concentrations from 0.1 nM to 1.0 PM. Cells in triplicate wells were resuspended by trypsinization and counted with a Coulter counter (Coulter Electronics, Hialeah, FL) at the indicated intervals.
The estrogen-dependent nature of the leiomyoma cells was assessed by maintaining cells in phenol red-free DF8 and 10% charcoal-stripped FBS for three passages before initiating experiments to determine their responsiveness to 17/3-estradiol.
Determination
of experimental conditions for maximum in vitro tamoxifen responsiveness Individual breast carcinoma cell lines have been shown to vary in their magnitudes of response to tamoxifen depending on serum type and concentration (16) (17) (18) . A pilot experiment was, therefore, conducted to determine the medium in which tamoxifen's effects on leiomyoma cells would be maximal. Tamoxifen responsiveness in ELT 3 was measured by plating cells in DF8 medium into 24-well plastic tissue culture dishes. Cells were allowed to proliferate for 72 h and then rinsed with sterile PBS. Individual wells were next refed with DFS containing tamoxifen citrate (Sigma) at concentrations from 0.1-10 pM and 10% FBS, 10% charcoal-stripped FBS, 2.5% FBS, or 2.5% charcoal-stripped FBS; 0.1% ethanol as a vehicle control was also added to each medium type. Cells in triplicate wells were resuspended by trypsinization and counted with a Coulter counter at 24-h intervals. In each well, the medium/treatment compound was changed after 72 h of exposure. Inhibition of proliferation was determined by expressing cell number in treatment groups as a percentage of cell numbers in the appropriate control medium and comparing values.
Tamoxifen responsiveness in ELT 3 cells
The tamoxifen responsiveness of leiomyoma cells was measured by plating ELT 3 in DFS medium into 24-well plastic tissue culture dishes (Coming). Cells were allowed to proliferate for 24-72 h. They were then rinsed with sterile PBS and refed DF8 containing 10% charcoal-stripped FBS plus 0.1% ethanol (vehicle control) or tamoxifen citrate (Sigma) at concentrations of 0.1-10 FM. Cells in triplicate wells were resuspended by trypsinization and counted with a Coulter counter at the indicated intervals. In each well, the medium/treatment compound was changed after 72 h of exposure.
The potential for tamoxifen to act as an estrogen agonist in leiomyoma cells was evaluated under estrogen-depleted conditions. ELT 3 cells were grown in phenol red-free DF8 plus 10% stripped serum for 3 passages, at which time cells were replated in estrogen-depleted medium in 24-well dishes and treated with tamoxifen at concentrations from 10 PM to 1.0 PM as described above.
Estrogen rescue of tamoxifen inhibition
To determine the potential contribution of nonreceptor-mediated events to the growth inhibition seen with tamoxifen, estrogen rescue experiments were performed. Cells were plated in DF8 medium in 24-well plastic tissue culture dishes (Corning). Cells were allowed to attach and proliferate for 24 h. They were then rinsed with sterile PBS and refed DF8 containing 10% charcoal-striuued FBS ulus 0.1% ethanol (vehicle control) or tam&fen at concentra&s of O.l', 1.0, and 5.0 PM. After 72 h, fresh medium containing ethanol or tamoxifen was added to the appropriate wells. In addition, in some wells previously containing tamoxifen, tamoxifen-containing medium was replaced with medium containing tamoxifen plus 178-estradiol at a concentration one tenth that of the tamoxifen concentration. Cells in triplicate wells were resuspended by trypsinization and counted with a Coulter counter at 24-h intervals.
I-Hydroxytammifen responsiveness in ELT 3 cells
The ability of the biologically active metabolite 4-hydroxytamoxifen to modulate ELT 3 growth was assessed by plating cells in DF8 medium into 24-well plastic tissue culture dishes. Cells were allowed to proliferate for 24 h and then rinsed with sterile PBS. Cells were refed DF8 containing 10% charcoal-stripped FBS plus 0.1% ethanol (vehicle control), 4-hydroxytamoxifen at concentrations from 0.01 nM to 0.1 PM, or tamoxifen at a concentration of 0.1 PM. Cells in triplicate wells were then resuspended by trypsinization and counted with a Coulter counter at 24-h intervals. In each well, the medium/treatment compound was changed after 72 h of exposure.
Modulation
of ELT 3 tumor growth in nude mouse xenograft system ELT 3 cells have been previously shown to produce tumors with a short latency when injected into athymic nude mice (9) . The ability of 17S-estradiol and tamoxifen to modulate the growth of tumors in this nude mouse xenograft system was determined by inoculating 8-to loweek-old intact female BALB/cAnNCr-nu/nu mice (NCI, Frederick, MD) SC with 2 X lo6 cells/site over each hip. Five to 9 days before inoculation, mice were anesthetized with methoxyflurane inhalation (Pitman-Moore, Mundelein, IL), separated into three treatment groups, and implanted with pellets of 178-estradiol [one 1.7-mg 60-day release pellet in each mouse (n = 5); Innovative Research, Toledo, OH], tamoxifen free base [one 25-mg or five 5-mg 60-day release tablets in each mouse (n = 5); Innovative Research], or placebo pellets (n = 6; Innovative Research) SC in the interscapular area. Fresh pellets were implanted 8 weeks after initial implantation. Immediately before inoculation, cells were harvested during log phase growth and resuspended in 0.1-0.2 ml serum-free DFS medium. Animals were observed weekly postinoculation, and tumor development was measured with a Vernier caliper. The mean cross-sectional area of each tumor was calculated as follows: (length/2) x (width/2) x n. Mice were killed by CO, inhalation when tumors grew to greater than 1.5 cm in diameter or approximately 120 days after inoculation. A portion of each tumor was frozen at -70 C Endo . 1995 Vol 136 . No 11 for subsequent analysis, and the remainder of the sample was fixed in 10% neutral buffered formalin for histopathological examination. Fixed tumor samples were embedded in paraffin by routine methods, sectioned, stained with hematoxylin and eosin, and examined under a microscope.
Statistical analysis
Differences between treatment groups in all experiments were evaluated using analysis of variance or Student's unpaired t test (StatView, Abacus Concepts, Berkeley, CA). All data points are reported as the mean 2 ssM.
ResuIts
In vitro estrogen and antiestrogen responses To determine whether the leiomyoma-derived cell line ELT 3 would respond to estrogen present in the growth medium, cells were grown in estrogen-depleted medium (phenol red-free medium and stripped serum) supplemented with 0.1 nM to 1.0 PM 17pestradiol. Estrogen produced a dose-dependent increase in proliferation in the cell line (Fig. 1) . The stimulation of cell growth was significant (P < 0.05) at all hormone concentrations examined. The maximal response was seen at the highest concentration (1.0 PM estradiol), which increased cell number approximately 2.2" fold over the control value after 96 h of continuous estrogen exposure. Passage of the cells in the absence of estrogen before plating did not affect the ability of the cells to proliferate in estrogen-depleted medium (data not shown). In addition, cells grown under these experimental conditions maintained their estrogen responsiveness. The fact that the estrogen receptor-negative leiomyoma cell line ELT 6 was not responsive to estradiol (data not shown) provides evidence that the effects of this hormone are specific and are not due to nonspecific stimulation of growth at higher concentrations.
Before embarking on large scale studies to examine the effects of the antiestrogen tamoxifen on cell line ELT 3, a pilot experiment was conducted to evaluate the effects of various serum types and concentrations on subsequent results. In the pilot experiment examining the effects of serum on tamoxifen responsiveness, the doubling times for cultures in all medium types were shortest on day 4 of the experiment (data not shown). Figure 2 illustrates the growth inhibition at this time point for each medium, expressed as a percentage of the appropriate control value. A comparison of the differing medium compositions revealed that, overall, tamoxifen exerted its greatest effects in 10% charcoal-stripped serum.
In 10% charcoal-stripped serum, the ability of tamoxifen to modulate the growth of leiomyoma cells was examined over a range of concentrations. Tamoxifen at concentrations of 0.1-10 PM produced a dose-dependent decrease in cell number that was significant at all concentrations tested. As shown in Fig. 3 , after 4 days of tamoxifen exposure, a 34% decrease in cell number was seen at the lowest concentration (0.1 PM). Some experimental variation was seen in three independent experiments conducted to evaluate the tamoxifen response; for example, inhibition with 0.1 FM tamoxifen ranged from 2034%. This inhibition increased with increasing tamoxifen concentrations, reaching 50%, 56%, 70%, and 77% at concentrations of 0.5,1.0,2.5, and 5.0 PM, respectively. Cells maintained in 10 PM tamoxifen appeared to slough off the dish at all time points examined and decreased in number throughout the course of the experiment. Some sloughing of cells was also observed to a much lesser extent at all remaining tamoxifen concentrations, but did not occur until later time points. At low concentrations, tamoxifen has been shown to act as a weak estrogen agonist in MCF-7 cells under estrogendeprived conditions (19). To assess the agonist activity of tamoxifen in leiomyoma cells, cells were maintained in estrogen-depleted conditions before plating. After plating, cells in estrogen-depleted medium were treated with tamoxifen at concentrations of 10 PM to 1.0 PM. As shown in Fig.  4 , tamoxifen continued to act as a pure antagonist in the absence of estrogen. Growth inhibition was seen at 0.1 and 1 .O PM tamoxifen concentrations, and no growth stimulation was evident at any of the submicromolar concentrations examined.
To assess the contribution of estrogen receptor-mediated and nonreceptor-mediated events to the growth inhibition seen with tamoxifen, the ability of estrogen to reverse this growth inhibition was evaluated. The results of these estrogen rescue experiments demonstrated that estradiol at a concentration one tenth that of tamoxifen was able to rescue the growth inhibition seen with 0.1 and 1.0 PM tamoxifen (Fig.  5 ). Cell numbers in 1 .O FM tamoxifen-containing wells were significantly lower than numbers in wells containing 1.0 PM tamoxifen plus 0.1 PM l'/&estradiol. In addition, cell numbers in the tamoxifen plus estradiol treatment group were not significantly different from numbers in nontreated control wells. Results were similar with 0.1 PM tamoxifen, where the addition of 10 nM 17/3-estradiol resulted in cell numbers significantly higher than those in wells maintained continuously in 0.1 FM tamoxifen. The numbers in the 0.1 pM tamoxifen plus estradiol treatment group were also not significantly different from those of nontreated control wells. In contrast, the growth inhibitory effects of 5.0 PM tamoxifen 420 were not rescued by the addition of 0.5 PM 17P-estradiol to the medium. No statistical difference in cell number was seen between 5.0 PM tamoxifen and tamoxifen plus estradiol treatment groups. Because tamoxifen is not extensively metabolized in vitro, the effect of 4-hydroxytamoxifen was assessed in leiomyoma cells and compared with that of tamoxifen. Treatment with the biologically active metabolite caused a dose-dependent decrease in cell number significantly more pronounced than that seen with tamoxifen under identical experimental conditions (P = 0.0098; Fig. 6 ). Cell numbers in wells containing 0.1 ELM tamoxifen were not statistically different from numbers in wells containing 1.0 nM 4-hydroxytamoxifen, indicating that similar effects occurred at loo-fold differences in compound concentrations. In addition, 4-hydroxytamoxifen was effective at inhibiting proliferation at concentrations as low as 0.01 nM.
In vivo modulation of nude mouse tumor growth by estradiol and tamoxifen Because the ELT 3 cell line is tumorigenic in nude mice (91, it was possible to examine the effects of estrogen and tamoxifen on tumor growth in viva. No significant difference in tumor latency was observed between l'/@stradiol-and placebotreated animals. When tumor size was examined, however, tumors in estrogen-treated animals were significantly larger than those in placebo-treated controls at each weekly time point examined after 8 weeks postinoculation. For example, at week 13 postinoculation, placebo-treated animals had a mean tumor area of 0.985 ? 0.215 cm', whereas estrogen-treated mice had a mean tumor area of 1.885 t 0.284 cm2 (P = 0.0436; Fig. 7A ). Tumor latency in an ELT 3 nude mouse xenograft system was significantly increased in tamoxifen-treated animals US.
estrogen-or placebo-treated controls (P = 0.00033 and 0.00018, respectively; Fig. 7B ). In addition, tumors in tamoxifen-treated mice were significantly smaller than those in placebo-treated animals. At the same week 13 point described above, placebotreated animals had a mean tumor area of 0.985 ? 0.215 cm*, and tamoxifen-treated mice showed a mean tumor area of 0.084 ? 0.022 cm* (P = 0.0243; Fig. 7A ).
On histological examination, nude mouse tumors from all groups appeared similar. The neoplasms were comprised of solid sheets and interwoven fascicles of extremely anaplastic mesenchymal cells with extensive cellular pleomorphism. Masses from estrogen-and placebo-treated animals contained multiple coalescing regions of necrosis, which, in conjunction with the high mitotic index seen in these tumors, was indicative of rapid growth (Fig. 8) . The masses from tamoxifen-treated animals were devoid of necrotic regions, indicating a slower proliferative rate in these lesions, consistent with the observed increase in tumor latency and decrease in tumor size observed for these lesions.
Discussion
These experiments describe the modulation of growth of leiomyoma cells by estradiol, tamoxifen, and Phydroxytamoxifen. In the estrogen receptor-positive leiomyoma celI line ELT 3, a proliferative response to estrogen was demonstrated by a dose-dependent increase in cell number with increasing concentration of 17/3-estradiol. Although there is little information The data shown are representative of three independent experiments. *, Significantly different from the control at P < 0.05. available on the response of human leiomyoma lines to in vitro estrogen administration, the maximum 2.2-fold increase in proliferation observed in response to estrogen is similar to the ahnost 2-fold increase that has been reported in the estrogenresponsive MCP7 breast carcinoma cell line and the 2.2-fold increase in the human ovarian adenocarcinoma cell line PEO4 (20, 21) . In these cell lines, responses to estradiol were also seen at concentrations up to 1.0 PM. In vitro tamoxifen responsiveness of breast cancer cell lines has been shown to vary significantly with experimental conditions (16-18). The presence or absence of estrogen in serum as well as the serum concentration can affect the response of a single cell line to tamoxifen by up to 75-fold (16). These observations have led to the suggestion that experimental conditions should be stringently reported when examining the in vitro effects of tamoxifen. Previous studies indicating that increasing serum concentration protects cells against the inhibitory effects of tamoxifen have expressed results as absolute values (e.g. micrograms of DNA or cell number) rather than as a percentage of the control value (17, 18 In a pilot study, we compared the effectiveness of tamoxifen at different concentrations in inhibiting proliferation by expressing our results as percentages of cell numbers in the appropriate control media. When we compared results in serum or charcoal-stripped serum at concentrations of 2.5% and lo%, leiomyoma cells maintained in 10% charcoalstripped serum showed the greatest degree of growth inhibition by tamoxifen. Within this medium type, inhibition was greatest at tamoxifen concentrations of 0.1-2.5 PM. Based on the results of our pilot study, we used medium containing 10% charcoal-stripped serum in all our subsequent tamoxifen and 4-hydroxytamoxifen experiments in vitro. Interestingly, in a report of doubling time as a percentage of the control value in T47D breast cancer cells treated with tamoxifen, the cells were most resistant to the effects of tamoxifen in 10% stripped serum (16). The reasons behind this difference in responsiveness between the breast cancer cell line and the leiomyoma cell line described here are not known, but future studies of tamoxifen's mechanism of action in ELT 3 cells should provide insight into the molecular basis of that difference.
A dose-dependent decrease in proliferation was demonstrated in response to in vitro tamoxifen exposure in 10% charcoal-stripped serum at tamoxifen concentrations ranging from 0.1-10 FM. The effects of the compound on proliferation in ELT 3 cells appear to be more pronounced than those reported in T47D cells under similar experimental conditions. A 70% inhibition of growth was demonstrated in ELT 3 cells after 4 days of 2.5 PM tamoxifen exposure, whereas T47D cells grown in 10% charcoal-stripped serum required 7.5 FM tamoxifen to produce a similar inhibition (16). These differences could be due to variation in levels of residual steroids or other factors in the stripped serum used by individual investigators. Responses to tamoxifen have been shown to be very tissue specific, however, providing an alternate explanation for the different magnitudes of response in the two cell types.
Tamoxifen in the absence of estrogen acts as a weak partial agonist at low concentrations in . Such agonist activity was not demonstrated in leiomyoma cells at concentrations as low as 10 PM. Tamoxifen, therefore, appears to behave as a complete antagonist in transformed myometrial cells. This action is in contrast to its agonist activity in other uterine components such as the endometrium (22-24). The basis for this differential response is not known at this time, but elucidating the underlying mechanism could be of value in the design of cell type-specific steroid hormone antagonists in the future.
Tamoxifen is not thought to be rapidly metabolized or inactivated by cells in vitro. This thinking is supported by the fact that tamoxifen responsiveness is similar in cells left in tamoxifen-containing medium for a period of days and in cells in which medium containing tamoxifen is changed regularly (25). Because of the lack of metabolism of tamoxifen in vitro, we evaluated the response of leiomyoma cells to the biologically active metabolite 4-hydroxytamoxifen. This metabolite has been shown to be a more potent growth inhibitor than its parent and has been reported to be 50-to 167-fold more effective than tamoxifen in inhibiting the proliferation of MCF7 cells in vitro (25). Our experiments with leiomyoma cells yielded similar results; 4-hydroxytamoxifen was lOOfold more effective than tamoxifen in inhibiting cell growth.
Estrogen rescue experiments indicate that growth inhibition at tamoxifen concentrations of 1.0 PM or less is due to estrogen receptor-mediated mechanisms. The inhibition of proliferation seen with 5.0 FM tamoxifen, however, was not readily reversible by estrogen, suggesting that growth inhibition at higher concentrations occurs through a mechanism independent of the estrogen receptor. This phenomenon has also been described in several mammary carcinoma cell lines, in which tamoxifen concentrations greater than 1.0 PM are though to act via estrogen receptor-independent pathways (17). One possible caveat to this interpretation is that at higher tamoxifen concentrations, cells become irreversibly growth arrested or committed to growth arrest and, thus, cannot be rescued by estrogen. Data exist indicating that tamoxifen can induce apoptosis (26), and commitment to an apoptotic pathway could be an example of such an irreversible type of growth arrest. At present, the mechanism of growth arrest by tamoxifen in our system is not known, and additional experiments to examine the mechanism of growth inhibition by triphenylethylenes in this model system are in progress.
The ability of ELT 3 to produce tumors with a short latency in athymic nude mice made possible the extension of in vitro data into an in vivo system. In a nude mouse xenograft assay, estradiol increased tumor size, but did not alter tumor latency compared with placebo treatments. Thus, it appears that estrogen does not alter the time course of events leading to tumor formation in the nude mouse system, but may increase the proliferative rates of tumors that do occur. This is similar to the observations in vitro, in which leiomyoma cells appear to be estrogen responsive rather than having an absolute require ment for estrogen. In addition, as intact female nude mice were used in these experiments, it is possible that the circulating levels of estrogen found in these animals were sufficient to support tumor formation in both estrogen-and placebo-treated mice.
Tamoxifen inhibited the latency of tumor formation in vivo, providing good correlation with in vitro data. Tamoxifen was not entirely effective in inhibiting tumor formation, however, as tumors did eventually arise in tamoxifen-treated animals. Histologically, these tumors appeared to be much slower growing than those arising in estrogen-or placebotreated animals, as evidenced by the lack of significant necrosis. Cytostatic effects have been demonstrated in vivo in breast carcinomas grown in nude mice (27) , and it may be that altered cell cycle transit times, similar to events reported in breast cancer cells in vitro (28,291 may be the mechanism by which tamoxifen inhibits the growth of ELT 3 cells in the nude mouse system. In addition, tamoxifen resistance has been reported to occur in clinical breast cancer (30), and the possibility exists that the tumors that grew in tamoxifentreated nude mice inoculated with leiomyoma cells were the clonal outgrowth of tamoxifen-nonresponsive cells.
Although tamoxifen responsiveness of myometrial tumors in women has not previously been examined experimentally, there are isolated reports of rapid increases in leiomyoma size in women taking tamoxifen (31, 32). The resulting tumors have not been well characterized, however, and it is possible that these isolated reports stem from the clonal expansion of a tamoxifen-resistant transformed myometrial cell. The likelihood of a resistant cell arising seems high because of the high tumor background in the large numbers of women taking tamoxifen. Tamoxifen is metabolized similarly in rats and humans (8) , and future studies using Eker rats in which leiomyomas arise with a high spontaneous frequency will allow further characterization of the effects of tamoxifen on uterine tumors in situ.
